[The efficacy of the chlorhexidine chip following scaling and root planing (SRP) and compared to SRP alone]

To evaluate the clinical efficacy and safety of the adjunctive use of Chlorhexidine Chip (CHX; commercial name, Perio Chip) following scaling and root planing (SRP) in periodontitis.

One center, blinded, randomized, split-mouth and active control study was designed. Sixty-five adult periodontitis patients were enrolled into the baseline after SRP. Each subject had at least one tooth with pocket depth of 5 mm or more and bleeding on probing (BOP) in each side of the mouth. Then the tooth was selected as a target and its parameters of probing depth (PD), attachment loss (AL), BOP, gingival index (GI), plaque index (PI) and staining index (SI) were recorded. Each side of mouth was randomly assigned to one of two treatments--drug placement after SRP or SRP alone. All the adverse events and parameters were recorded at time of 3-month, 6-month and meanwhile the patients received oral hygiene instruction and scaling. The same was conducted at 6-week, 4.5-month except for recording of parameters and scaling of the target teeth.

Reduction of PD and gain of attachment at 6-month in group of SRP plus CHX (1.32 mm, 0.94 mm) were significantly higher than those in group of SRP alone (0.77 mm, 0.40 mm) (P < 0.001). Forty-four point six percent (44.6%) of patients reflected adverse reactions related to drug placement. Toothaches, the main reactions, were mild to moderate in nature and spontaneously resolved within 2-4 days.

The chlorhexidine chip is indeed a safe and effective control-delivered drug for topical use when patient in his supportive periodontal therapy.